Skip to main content
Premium Trial:

Request an Annual Quote

ABI to Help Cepheid Build Anthrax-Detecting Technology for US Gov t

NEW YORK, Oct. 16 - Applied Biosystems will help Cepheid develop bioterror agent-detecting reagents for use with Cepheid's GeneXpert system in a broader government-funded anti-anthrax project, Cepheid said today.

 

The reagents will likely be used by the US Postal Service as part of a broad agreement that called for Cepheid and other companies to develop tools than can detect anthrax.

 

As GenomeWeb reported in May, the USPS awarded Cepheid $750,000 to participate in a pilot program designed to devise systems to detect anthrax attacks. Specifically, the deal makes Cepheid part of a team led by US aerospace giant Northrop Grumman that will spearhead a $3.7 million plan to evaluate "DNA-based biothreat-detection technology," Cepheid said at the time.

 

Depending on the outcome of this pilot program, Cepheid had said the USPC would award a "multi-million-dollar" contract by the end of September to install the technology in most of its 300 automatic mail-sorting facilities across the US. It was not immediately clear whether this deal with ABI signals an increased interest by the USPS or merely a continuation of the pilot program; officials for Cepheid, based in Sunnyvale, Calif., were not available for comment at deadline.

 

Under the pilot deal, Cepheid would manufacture the GeneXpert DNA tests and all requisite reagents while Northrop Grumman would sell the systems.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.